Abstract: Five-year survival of ovarian cancer is 30%-45% for its non-obvious clinical symptoms, limited screening methods and advanced stage at initial diagnosis, which seriously threatens the health of women. Immunotherapy, especially immune checkpoint blockade, has been approved for treatment for patients with metastatic or recurrent multiple cancers for its durable anti-tumor effect. Also, the research progress of immunotherapy provides clinical management of ovarian cancer patients with new opportunities and challenges.

Key words: Ovarian cancer, Immunotherapy, Immune checkpoint blockade